Prospective evaluation of hepatitis B 1762 T/1764 A mutations on hepatocellular carcinoma development in Shanghai, china

Cancer Epidemiology Biomarkers and Prevention

Volumn 18, Issue 2, 2009, Pages 590-594

  Yuan, Jian Min ^a,b   Ambinder, Alex ^c   Fan, Yunhua ^a   Gao, Yu Tang ^d   Yu, Mimi C ^a   Groopman, John D ^c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c The Johns Hopkins University   (United States)

^d SHANGHAI CANCER INSTITUTE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIGEN;

ADULT; ARTICLE; CANCER RISK; CHINA; CLINICAL ARTICLE; CONTROLLED STUDY; GENE MUTATION; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; PRIORITY JOURNAL;

CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; CHINA; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; INCIDENCE; LIVER NEOPLASMS; LOGISTIC MODELS; MALE; MIDDLE AGED; MUTATION; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 60649085236     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-08-0966     Document Type: Article

References (26)

1. Arbuthnot P, Kew M. Hepatitis B virus and hepatocellular carcinoma. Int J Exp Pathol 2001;82:77-100.
2. HouJ,LauGK,ChengJ,etal. T1762/A1764variantsofthebasalcore promoter of hepatitis B virus; serological and clinical correlations in Chinese patients. Liver 1999;19:411-7.
3. Baptista M, Kramvis A, Kew MC. High prevalence of 1762(T) 1764(A) mutations in the basic core promoter of hepatitis B virus isolated from black Africans with hepatocellular carcinoma compared with asymptomatic carriers. Hepatology 1999;29:946-53.
4. Kuang SY, Jackson PE, Wang JB, et al. Specific mutations of hepatitis B virus in plasma predict liver cancer development. Proc Natl Acad Sci USA 2004;101:3575-80.
5. Chen JG, Kuang SY, Egner PA, et al. Acceleration to death from liver cancer in people with hepatitis B viral mutations detected in plasma by mass spectrometry. Cancer Epidemiol Biomarkers Prev 2007;16:1213-8.
6. Yang HI, Yeh SH, Chen PJ, et al. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst 2008;100:1134-43.
7. Ross RK, Yuan JM, Yu MC, et al. Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet 1992;339:943-6.
8. Yuan JM, Ross RK, Wang XL, et al. Morbidity and mortality in relation to cigarette smoking in Shanghai, China. A prospective male cohort study. JAMA 1996;275:1646-50.
9. Kuang SY, Lekawanvijit S, Maneekarn N, et al. Hepatitis B 1762T/1764A mutations, hepatitis C infection, and codon 249 p53 mutations in hepatocellular carcinomas from Thailand. Cancer Epidemiol Biomarkers Prev 2005;14:380-4.
10. Breslow NE, Day NE. Statistical methods in cancer research. Volume 1. The analysis of case-control studies. Lyon: IARC Scientific Publication; 1980.
11. Yuan JM, Gao YT, Ong CN, Ross RK, Yu MC. Prediagnostic level of serum retinol in relation to reduced risk of hepatocellular carcinoma. J Natl Cancer Inst 2006;98:482-90.
12. Qian GS, Ross RK, Yu MC, et al. A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China. Cancer Epidemiol Biomarkers Prev 1994;3:3-10.
13. Nieters A, Yuan JM, Sun CL, et al. Effect of cytokine genotypes on the hepatitis B virus-hepatocellular carcinoma association. Cancer 2005;103:740-8.
14. Hunt CM, McGill JM, Allen MI, Condreay LD. Clinical relevance of hepatitis B viral mutations. Hepatology 2000;31:1037-44.
15. Takahashi K, Aoyama K, Ohno N, et al. The precore/core promoter mutant (T1762A1764) of hepatitis B virus: clinical significance and an easy method for detection. J Gen Virol 1995;76:3159-64.
16. Buckwold VE, Xu Z, Chen M, Yen TS, Ou JH. Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replication. J Virol 1996;70:5845-51.
17. Tang H, Raney AK, McLachlan A. Replication of the wild type and a natural hepatitis B virus nucleocapsid promoter variant is differentially regulated by nuclear hormone receptors in cell culture. J Virol 2001;75:8937-48.
18. Yu X, Mertz JE. Distinct modes of regulation of transcription of hepatitis B virus by the nuclear receptors HNF4α and COUP-TF1. J Virol 2003;77:2489-99.
19. Kidd-Ljunggren K, Oberg M, Kidd AH. The hepatitis B virus X gene: analysis of functional domain variation and gene phylogeny using multiple sequences. J Gen Virol 1995;76:2119-30.
20. Li J, Buckwold VE, Hon MW, Ou JH. Mechanism of suppression of hepatitis B virus precore RNA transcription by a frequent double mutation. J Virol 1999;73:1239-44.
21. Tong S, Kim KH, Chante C, Wands J, Li J. Hepatitis B virus e antigen variants. Int J Med Sci 2005;2:2-7.
22. Parekh S, Zoulim F, Ahn SH, et al. Genome replication, virion secretion, and e antigen expression of naturally occurring hepatitis B virus core promoter mutants. J Virol 2003;77:6601-12.
23. Koike K. Hepatitis B virus HBx gene and hepatocarcinogenesis. Intervirology 1995;38:134-42.
24. Hsia CC, Yuwen H, Tabor E. Hot-spot mutations in hepatitis B virus X gene in hepatocellular carcinoma. Lancet 1996;348:625-6.
25. Sirma H, Giannini C, Poussin K, et al. Hepatitis B virus X mutants, present in hepatocellular carcinoma tissue abrogate both the antiproliferative and transactivation effects of HBx. Oncogene 1999;18:4848-59.
26. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73.